633 related articles for article (PubMed ID: 28892721)
1. Glial and neuroinflammatory targets for treating substance use disorders.
Bachtell RK; Jones JD; Heinzerling KG; Beardsley PM; Comer SD
Drug Alcohol Depend; 2017 Nov; 180():156-170. PubMed ID: 28892721
[TBL] [Abstract][Full Text] [Related]
2. Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances.
Cooper ZD; Jones JD; Comer SD
Expert Opin Investig Drugs; 2012 Feb; 21(2):169-78. PubMed ID: 22233449
[TBL] [Abstract][Full Text] [Related]
3. Glial mechanisms underlying substance use disorders.
Linker KE; Cross SJ; Leslie FM
Eur J Neurosci; 2019 Aug; 50(3):2574-2589. PubMed ID: 30240518
[TBL] [Abstract][Full Text] [Related]
4. Glial modulators as potential treatments of psychostimulant abuse.
Beardsley PM; Hauser KF
Adv Pharmacol; 2014; 69():1-69. PubMed ID: 24484974
[TBL] [Abstract][Full Text] [Related]
5. Potential of Glial Cell Modulators in the Management of Substance Use Disorders.
Jones JD
CNS Drugs; 2020 Jul; 34(7):697-722. PubMed ID: 32246400
[TBL] [Abstract][Full Text] [Related]
6. Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?
Niciu MJ; Henter ID; Sanacora G; Zarate CA
World J Biol Psychiatry; 2014 Jan; 15(1):2-16. PubMed ID: 24024876
[TBL] [Abstract][Full Text] [Related]
7. Glial and Neuroimmune Mechanisms as Critical Modulators of Drug Use and Abuse.
Lacagnina MJ; Rivera PD; Bilbo SD
Neuropsychopharmacology; 2017 Jan; 42(1):156-177. PubMed ID: 27402494
[TBL] [Abstract][Full Text] [Related]
8. The role of glial cells in drug abuse.
Miguel-Hidalgo JJ
Curr Drug Abuse Rev; 2009 Jan; 2(1):72-82. PubMed ID: 19630738
[TBL] [Abstract][Full Text] [Related]
9. Influence of psychostimulants and opioids on epigenetic modification of class III histone deacetylase (HDAC)-sirtuins in glial cells.
Sivalingam K; Doke M; Khan MA; Samikkannu T
Sci Rep; 2021 Oct; 11(1):21335. PubMed ID: 34716387
[TBL] [Abstract][Full Text] [Related]
10. The Crosstalk Between Neurons and Glia in Methamphetamine-Induced Neuroinflammation.
Shi S; Chen T; Zhao M
Neurochem Res; 2022 Apr; 47(4):872-884. PubMed ID: 34982394
[TBL] [Abstract][Full Text] [Related]
11. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs.
Cunha-Oliveira T; Rego AC; Oliveira CR
Brain Res Rev; 2008 Jun; 58(1):192-208. PubMed ID: 18440072
[TBL] [Abstract][Full Text] [Related]
12. Glial regulation of synaptic function in models of addiction.
Stellwagen D; Kemp GM; Valade S; Chambon J
Curr Opin Neurobiol; 2019 Aug; 57():179-185. PubMed ID: 31163290
[TBL] [Abstract][Full Text] [Related]
13. Opioids, gliosis and central immunomodulation.
Kadhim S; McDonald J; Lambert DG
J Anesth; 2018 Oct; 32(5):756-767. PubMed ID: 30054718
[TBL] [Abstract][Full Text] [Related]
14. Microglial alterations induced by psychoactive drugs: A possible mechanism in substance use disorder?
Catale C; Bussone S; Lo Iacono L; Carola V
Semin Cell Dev Biol; 2019 Oct; 94():164-175. PubMed ID: 31004753
[TBL] [Abstract][Full Text] [Related]
15. Dynamic changes in dopaminergic neurotransmission induced by a low concentration of bisphenol-A in neurones and astrocytes.
Miyatake M; Miyagawa K; Mizuo K; Narita M; Suzuki T
J Neuroendocrinol; 2006 Jun; 18(6):434-44. PubMed ID: 16684133
[TBL] [Abstract][Full Text] [Related]
16. Novel celecoxib analogues inhibit glial production of prostaglandin E2, nitric oxide, and oxygen radicals reverting the neuroinflammatory responses induced by misfolded prion protein fragment 90-231 or lipopolysaccharide.
Villa V; Thellung S; Bajetto A; Gatta E; Robello M; Novelli F; Tasso B; Tonelli M; Florio T
Pharmacol Res; 2016 Nov; 113(Pt A):500-514. PubMed ID: 27667770
[TBL] [Abstract][Full Text] [Related]
17. [Implication of neuron-glia interaction in the molecular mechanism of drug dependence].
Narita M; Kuzumaki N; Suzuki T
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2008 Feb; 43(1):13-8. PubMed ID: 18402052
[No Abstract] [Full Text] [Related]
18. Endomorphin analog analgesics with reduced abuse liability, respiratory depression, motor impairment, tolerance, and glial activation relative to morphine.
Zadina JE; Nilges MR; Morgenweck J; Zhang X; Hackler L; Fasold MB
Neuropharmacology; 2016 Jun; 105():215-227. PubMed ID: 26748051
[TBL] [Abstract][Full Text] [Related]
19. Psychostimulants: Basic and Clinical Pharmacology.
McCreary AC; Müller CP; Filip M
Int Rev Neurobiol; 2015; 120():41-83. PubMed ID: 26070753
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
